Bio-Thera Kicks Off Ustekinumab Trial
Phase I Study Follows Similar Efforts From Rival Stelara Biosimilars
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.
